Cargando…

Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study

BACKGROUND: Gonorrhea is a highly prevalent sexually transmitted infection and an urgent public health concern due to increasing antibiotic resistance. Only ceftriaxone remains as the recommended treatment in the U.S. The prospect of approval of new anti-gonococcal antibiotics raises the question of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reichert, E, Yaesoubi, R, Rönn, MM, Gift, TL, Salomon, JA, Grad, YH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949214/
https://www.ncbi.nlm.nih.gov/pubmed/36824857
http://dx.doi.org/10.1101/2023.02.14.23285710
_version_ 1784892927650037760
author Reichert, E
Yaesoubi, R
Rönn, MM
Gift, TL
Salomon, JA
Grad, YH
author_facet Reichert, E
Yaesoubi, R
Rönn, MM
Gift, TL
Salomon, JA
Grad, YH
author_sort Reichert, E
collection PubMed
description BACKGROUND: Gonorrhea is a highly prevalent sexually transmitted infection and an urgent public health concern due to increasing antibiotic resistance. Only ceftriaxone remains as the recommended treatment in the U.S. The prospect of approval of new anti-gonococcal antibiotics raises the question of how to deploy a new drug to maximize its clinically useful lifespan. METHODS: We used a compartmental model of gonorrhea transmission in the U.S. population of men who have sex with men to compare strategies for introducing a new antibiotic for gonorrhea treatment. The strategies tested included holding the new antibiotic in reserve until the current therapy reached a threshold prevalence of resistance; using either drug, considering immediate and gradual introduction of the new drug; and combination therapy. The primary outcome of interest was the time until 5% prevalence of resistance to both the novel drug and to the current first-line drug (ceftriaxone). FINDINGS: The reserve strategy was consistently inferior for mitigating antibiotic resistance under the parameter space explored. The reserve strategy was increasingly outperformed by the other strategies as the probability of de novo resistance emergence decreased and as the fitness costs associated with resistance increased. Combination therapy tended to prolong the development of antibiotic resistance and minimize the number of annual gonococcal infections. INTERPRETATION: Our study argues for rapid introduction of new anti-gonococcal antibiotics, recognizing that the feasibility of each strategy must incorporate cost, safety, and other practical concerns. The analyses should be revisited once robust estimates of key parameters–likelihood of emergence of resistance and fitness costs of resistance for the new antibiotic–are available. FUNDING: U.S. Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases
format Online
Article
Text
id pubmed-9949214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-99492142023-02-24 Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study Reichert, E Yaesoubi, R Rönn, MM Gift, TL Salomon, JA Grad, YH medRxiv Article BACKGROUND: Gonorrhea is a highly prevalent sexually transmitted infection and an urgent public health concern due to increasing antibiotic resistance. Only ceftriaxone remains as the recommended treatment in the U.S. The prospect of approval of new anti-gonococcal antibiotics raises the question of how to deploy a new drug to maximize its clinically useful lifespan. METHODS: We used a compartmental model of gonorrhea transmission in the U.S. population of men who have sex with men to compare strategies for introducing a new antibiotic for gonorrhea treatment. The strategies tested included holding the new antibiotic in reserve until the current therapy reached a threshold prevalence of resistance; using either drug, considering immediate and gradual introduction of the new drug; and combination therapy. The primary outcome of interest was the time until 5% prevalence of resistance to both the novel drug and to the current first-line drug (ceftriaxone). FINDINGS: The reserve strategy was consistently inferior for mitigating antibiotic resistance under the parameter space explored. The reserve strategy was increasingly outperformed by the other strategies as the probability of de novo resistance emergence decreased and as the fitness costs associated with resistance increased. Combination therapy tended to prolong the development of antibiotic resistance and minimize the number of annual gonococcal infections. INTERPRETATION: Our study argues for rapid introduction of new anti-gonococcal antibiotics, recognizing that the feasibility of each strategy must incorporate cost, safety, and other practical concerns. The analyses should be revisited once robust estimates of key parameters–likelihood of emergence of resistance and fitness costs of resistance for the new antibiotic–are available. FUNDING: U.S. Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases Cold Spring Harbor Laboratory 2023-02-17 /pmc/articles/PMC9949214/ /pubmed/36824857 http://dx.doi.org/10.1101/2023.02.14.23285710 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Reichert, E
Yaesoubi, R
Rönn, MM
Gift, TL
Salomon, JA
Grad, YH
Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title_full Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title_fullStr Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title_full_unstemmed Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title_short Resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
title_sort resistance-minimizing strategies for introducing a novel antibiotic for gonorrhea treatment: a mathematical modeling study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949214/
https://www.ncbi.nlm.nih.gov/pubmed/36824857
http://dx.doi.org/10.1101/2023.02.14.23285710
work_keys_str_mv AT reicherte resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy
AT yaesoubir resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy
AT ronnmm resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy
AT gifttl resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy
AT salomonja resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy
AT gradyh resistanceminimizingstrategiesforintroducinganovelantibioticforgonorrheatreatmentamathematicalmodelingstudy